DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical...
Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at...
Petra Capital Properties is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with...
